LEADER 10896nam 2200493 450 001 9910677499803321 005 20230427112353.0 010 $a1-394-16770-9 010 $a1-394-16769-5 035 $a(MiAaPQ)EBC7187374 035 $a(Au-PeEL)EBL7187374 035 $a(CKB)26068930200041 035 $a(EXLCZ)9926068930200041 100 $a20230427d2023 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAdvances in Novel Formulations for Drug Delivery /$fedited by Raj K. Keservani, Rajesh Kumar Kesharwani, and Anil K. Sharma 210 1$aHoboken, NJ ;$aBeverly, MA :$cJohn Wiley & Sons, Inc. :$cScrivener Publishing LLC,$d[2023] 210 4$dİ2023 215 $a1 online resource (576 pages) 311 08$aPrint version: Keservani, Raj K. Advances in Novel Formulations for Drug Delivery Newark : John Wiley & Sons, Incorporated,c2023 9781394166435 320 $aIncludes bibliographical references and index. 327 $aCover -- Title Page -- Copyright Page -- Contents -- Preface -- Part I: Novel Drug Carriers and Therapeutics -- Chapter 1 Nanoarchitectured Materials: Their Applications and Present Scenarios in Drug Delivery -- 1.1 Introduction -- 1.2 Liposomes -- 1.3 Nanoparticles -- 1.3.1 Nanoparticles in Drug Delivery -- 1.4 Nanoemulsions -- 1.4.1 Advantages and Shortcomings of Nanoemulsions -- 1.4.2 Application of Nanoemulsion in Drug Delivery -- 1.5 Dendrimers -- 1.5.1 Synthesis of Dendrimers -- 1.5.2 Advantages of Dendrimers -- 1.5.3 Applications of Dendrimers in Drug Delivery -- 1.6 Aquasomes -- 1.6.1 Properties of Aquasomes -- 1.6.2 Application of Aquasomes in Drug Delivery -- 1.7 Nanogel -- 1.7.1 Properties of Nanogels -- 1.7.2 Nanogels in Drug Delivery -- 1.8 Quantum Dots -- 1.8.1 Applications of Quantum Dots in Drug Delivery -- 1.9 Carbon Nanotubes -- 1.9.1 Features of Carbon Nanotubes -- 1.9.2 Carbon Nanotubes in Drug Delivery -- References -- Chapter 2 Nanopharmaceuticals for Drug Delivery -- 2.1 Introduction -- 2.2 What Are Nanopharmaceuticals and What Do They Do? -- 2.3 Nanopharmaceuticals Importance -- 2.4 Nanotechnology -- 2.5 Pharmaceutical Companies and Nanotechnology -- 2.6 Applications and Advantages of Nanopharmaceuticals as Drug Carriers -- 2.7 Characteristics of Nanoparticles in Nanopharmaceuticals -- 2.7.1 Particle Size -- 2.7.2 Surface Properties of Nanoparticles -- 2.7.3 Drug Loading -- 2.7.4 Drug Release -- 2.8 Targeted Drug Delivery -- 2.9 Types of Nanoparticles -- 2.10 Nanoparticle Preparation Methods -- 2.11 Evaluation of Nanoparticles -- 2.12 Efficiency of Drug Entrapment -- 2.13 Particle Shape -- 2.14 Size of the Particles -- 2.15 Zeta Potential -- 2.16 Rise of Nanopharmaceuticals -- 2.17 Nanopharmaceuticals Approval Regulations (FDA Rules & -- Regulations) -- 2.18 Conclusions and Prospects for the Future -- References. 327 $aChapter 3 Applications and Prospects of Nanopharmaceuticals Delivery -- 3.1 Introduction -- 3.2 Nanopharmaceuticals -- 3.3 Development of Nanopharmaceuticals -- 3.3.1 From Lab to the Marketplace -- 3.3.2 Techniques -- 3.3.3 Cost -- 3.3.4 Ethics -- 3.3.5 Nanopharmaceuticals Approval Regulations (FDA Rules & -- Regulations) -- 3.4 Clinical Applications of Nanotechnology -- 3.4.1 Diagnostic Applications -- 3.4.1.1 Detection -- 3.4.1.2 Protein Chips -- 3.4.1.3 Individual Target Probes -- 3.4.1.4 Nanotechnology as a Tool in Imaging -- 3.4.1.5 Sparse Cell Detection -- 3.4.2 Therapeutic Applications -- 3.4.2.1 Surfaces -- 3.4.2.2 Gene Delivery -- 3.4.2.3 Drug Delivery -- 3.4.2.4 Liposomes -- 3.4.2.5 Nanotechnology in Orthopedic Applications -- 3.4.2.6 Nanotechnology in Cardiac Therapy -- 3.4.2.7 Nanotechnology in Dental Care -- 3.4.2.8 Biomolecular Engineering -- 3.4.2.9 Biopharmaceuticals -- 3.5 Nanopharmaceuticals Delivery-Recent Applications -- 3.5.1 Nanoparticulate Systems for Vaccine -- 3.5.1.1 Polyanhydride-Based NPs -- 3.5.1.2 Biodegradable Synthetic PLGA NPs -- 3.5.1.3 Liposome-Based NPs -- 3.5.1.4 Polysaccharide-Based NPs -- 3.5.2 Chemotherapy -- 3.5.2.1 Increasing the Concentration of Chemotherapeutic Agents in Tumor Tissue -- 3.5.3 Drug/Gene Delivery -- 3.5.3.1 Nanoparticles Used in Drug Delivery System -- 3.5.3.2 Cellulose -- 3.6 Nanotechnology in Neurodegenerative Disorders Treatment -- 3.7 Future Perspective -- 3.8 Issues with Current Nanopharmaceutical Concepts -- 3.8.1 Large-Scale Manufacturing -- 3.8.2 Biological Challenges -- 3.8.3 Intellectual Property (IP) -- 3.8.4 Biocompatibility and Safety -- 3.8.5 Government Regulations -- 3.9 Conclusion -- References -- Chapter 4 Nanomedicine Regulation and Future Prospects -- 4.1 Introduction -- 4.2 Importance of Regulation of Nanomedicine. 327 $a4.3 Regulatory Challenges Faced by Nanomaterial in Medicine -- 4.3.1 Performing Various Functions -- 4.3.2 Nanomedicine Classification Issues -- 4.3.3 Variation in Size of the Particle -- 4.3.4 Manufacturing Process -- 4.3.5 Difficulties to Create CQA -- 4.3.6 Nanotoxicology and Cellular Response -- 4.3.7 Administering Right Doses -- 4.3.8 Pharmacokinetics -- 4.3.9 Developing Guidelines -- 4.4 Nanomedicine Future Aspects -- 4.5 Challenges that Threaten the Future of Nanomedicine -- 4.5.1 Financial Crisis -- 4.5.2 Lack of Confidence -- 4.5.3 Potential Dangers -- 4.5.4 Unsuccessful Patenting -- 4.5.5 Breakdowns in the Pharmaceuticals and Financial Markets -- 4.5.6 Limited Regulation -- 4.6 Future Prospects for Nanomedicine -- 4.6.1 Emerging Nanomaterials -- 4.6.2 Personalized Nanomedicine -- 4.6.3 Nanorobots and Nanodevices -- 4.6.4 Orthopedic Augmentations and Cytocompatibility -- 4.6.5 Cardiology and Nanotechnology -- 4.6.6 Cancer and Nanotechnology -- 4.6.7 NAPT -- 4.6.8 Gene, Protein, Lab-on-a-Chip Devices -- 4.6.9 Polymeric Nanoparticles in Medicine -- References -- Chapter 5 Nanotechnology Application in Drug Delivery for Medicinal Plants -- 5.1 Introduction -- 5.1.1 Nanodrug Delivery Systems (NDDS) -- 5.2 Nanoherbals -- 5.2.1 Cucuma longa (Cucurmin) -- 5.2.2 Gingko biloba -- 5.2.3 Artemisia -- 5.2.4 Silybum marianum-Silymarin -- 5.2.5 Salvia miltiorrhiza (Danshen) -- 5.2.6 Glycyrrhiza glabra (L.) -- 5.2.7 Camellia sinensis (Green tea) -- 5.2.8 Camptotheca acuminata -- 5.2.9 Leea indica -- 5.2.10 Ziziphus mauritiana (Malay apple) -- 5.2.11 Cuscuta chinensis -- 5.3 Conclusion -- References -- Chapter 6 Nanosystems Trends in Nutraceutical Delivery -- 6.1 Introduction -- 6.2 Classification of Nutraceuticals -- 6.3 Biopharmaceutical Issues Associated with Nutraceuticals -- 6.4 Nanosystems for Delivery of Nutraceuticals -- 6.4.1 Nanoemulsions. 327 $a6.4.2 Self-Emulsifying Systems -- 6.4.3 Solid Lipid Nanoparticles and Nanostructured Lipid Carriers -- 6.4.4 Liposomes -- 6.4.5 Polymeric Nanoparticles -- 6.4.6 Inorganic Nanoparticles -- 6.5 Challenges -- 6.6 Market Potential -- 6.7 Conclusion and Perspective -- References -- Chapter 7 Nanoencapsulated Systems for Delivery of Phytopharmaceuticals -- 7.1 Introduction -- 7.1.1 Nanoencapsulation Techniques in Phytopharmaceuticals -- 7.1.1.1 Physical-Chemical Techniques -- 7.1.1.2 Chemicals Techniques -- 7.1.1.3 Mechanical Techniques -- 7.1.2 Characterization of Nanoencapsulates -- 7.1.2.1 Morphological Characterization -- 7.1.2.2 Physicochemical Characterization -- 7.1.3 Nanoencapsulated Systems for Free Delivery of Phytopharmaceuticals -- 7.1.4 Studies to Evaluate Phytopharmaceuticals Nanoencapsulates -- 7.2 Conclusions -- References -- Chapter 8 Topical Drug Delivery Using Liposomes and Liquid Crystalline Phases for Skin Cancer Therapy -- 8.1 Introduction -- 8.2 Liposomes for Topical Application -- 8.2.1 Development of Liposomal Nanoparticles -- 8.3 Liquid Crystals and Liquid Crystalline Nanodispersions for Topical Application -- 8.3.1 Characterization Techniques -- 8.4 Physical Methods Applied to Nanoparticles Delivery -- 8.4.1 Sonophoresis -- 8.4.2 Microneedles -- 8.5 Conclusions and Perspectives -- Acknowledgements -- References -- Chapter 9 Vesicular Drug Delivery in Arthritis Treatment -- 9.1 Introduction -- 9.2 Skin Penetration Pathways -- 9.2.1 Intercellular Pathway -- 9.2.2 Transcellular Pathway -- 9.2.3 Appendgeal Pathway -- 9.3 Principles of Drug Permeation Through Skin -- 9.4 Problems Associated with Conventional Dosage Forms -- 9.5 Novel Treatment Strategies for Arthritis -- 9.5.1 Traditional Liposomes as Skin Drug Delivery Systems -- 9.5.2 Transferosomes (Ultradeformable Liposomes) as Skin Drug Delivery Systems. 327 $a9.5.3 Ethosomes as Skin Drug Delivery Systems -- 9.5.4 Niosomes as Skin Drug Delivery Systems -- 9.6 Conclusion and Future Perspectives -- References -- Chapter 10 Perspectives of Novel Drug Delivery in Mycoses -- 10.1 Introduction -- 10.2 Role of Conventional Drugs in Antifungal Therapy -- 10.3 Mechanism of Action of Conventional Antifungals -- 10.4 Summary of Nanoparticles and Their Role in Antifungal Therapy -- 10.4.1 Lipid Nanoparticles -- 10.4.2 Liposome -- 10.4.3 Transfersomes -- 10.4.4 Transethosomes -- 10.4.5 Solid Lipid Nanoparticles (SLN) -- 10.4.6 Nanostructured Lipid Carriers (NLC) -- 10.4.7 Polymer Lipid Hybrid Nanoparticles (PLN) -- 10.4.8 Polymeric Nanoparticles -- 10.4.9 Microsponge and Nanosponge Systems -- 10.4.10 Polymeric Micelles -- 10.4.11 Polymersomes -- 10.4.12 Dendrimers -- 10.4.13 Metallic Nanoparticles -- 10.5 Other Drug Delivery Systems -- 10.5.1 Niosomes -- 10.5.2 Spanlastics -- 10.5.3 Microemulsions and Nanoemulsions -- 10.5.4 Silicon Dioxide Nanoparticles -- 10.6 Conclusion -- References -- Chapter 11 Nano-Based Drug Delivery in Eliminating Tuberculosis -- 11.1 Introduction -- 11.1.1 Latent and Active Tuberculosis -- 11.1.2 Multidrug-Resistant Tuberculosis (MDR-TB) -- 11.1.3 Extensively Drug-Resistant TB -- 11.2 Antitubercular Therapy -- 11.3 Therapies Based on Nanotechnology -- 11.3.1 Nanoparticles for Anti-TB Therapy -- 11.3.2 Advantages and Disadvantages of Nanoparticles -- 11.3.3 Types of Nanoparticles and Their Characteristics -- 11.3.3.1 TB Dendrimers -- 11.3.3.2 Cyclodextrins -- 11.3.3.3 Polymeric Micelles -- 11.3.3.4 Liposomes -- 11.3.3.5 Nanoemulsions -- 11.3.3.6 Solid Lipid Nanoparticles -- 11.3.3.7 Niosomes -- 11.3.3.8 Polymeric Nanoparticles -- 11.4 Routes of Administration of Nanoparticles -- 11.4.1 Oral Administration of Nanoparticles -- 11.4.2 Inhalational Administration of Nanoparticles. 327 $a11.4.3 Intravenous Administration of Nanoparticles. 606 $aDrug delivery systems 615 0$aDrug delivery systems. 676 $a615.6 702 $aKeservani$b Raj K. 702 $aKesharwani$b Rajesh Kumar 702 $aSharma$b Anil K. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910677499803321 996 $aAdvances in Novel Formulations for Drug Delivery$93301842 997 $aUNINA LEADER 01381nam a2200349 i 4500 001 991000686289707536 005 20020507172246.0 008 950915s1981 uk ||| | eng 020 $a0201135078 035 $ab10743091-39ule_inst 035 $aLE01300704$9ExL 040 $aDip.to Matematica$beng 082 0 $a530.155 082 0 $a539.72 084 $aAMS 47N50 100 1 $aBiedenharn, L. C.$0534648 245 10$aAngular momentum in quantum physics :$btheory and application /$cL. C. Biedenharn, J. D. Louck ; with a foreword by Peter A. Carruthers 260 $aReading, MA :$bAddison-Wesley,$c1981 300 $axxxii, 716 p. :$bill. ;$c24 cm 490 0 $aEncyclopedia of mathematics and its applications ;$v8 500 $a"Bibliography of tables": p. 667-669 500 $aIncludes bibliographical references and indexes 650 0$aAngular momentum 650 0$aApplications in quantum physics 650 0$aQuantum theory 700 1 $aLouck, James D.$eauthor$4http://id.loc.gov/vocabulary/relators/aut$044887 907 $a.b10743091$b23-02-17$c28-06-02 912 $a991000686289707536 945 $aLE013 47N BIE12 (1981)$g1$i2013000035796$lle013$o-$pE0.00$q-$rl$s- $t0$u2$v0$w2$x0$y.i10834540$z28-06-02 996 $aAngular momentum in quantum physics$91012937 997 $aUNISALENTO 998 $ale013$b01-01-95$cm$da $e-$feng$guk $h0$i1 LEADER 02735nam 2200553Ia 450 001 9910130580903321 005 20200520144314.0 010 $a3-642-33380-X 024 7 $a10.1007/978-3-642-33380-4 035 $a(CKB)3400000000102778 035 $a(SSID)ssj0000880075 035 $a(PQKBManifestationID)11559382 035 $a(PQKBTitleCode)TC0000880075 035 $a(PQKBWorkID)10872781 035 $a(PQKB)11187877 035 $a(DE-He213)978-3-642-33380-4 035 $a(MiAaPQ)EBC3071013 035 $a(PPN)16832430X 035 $a(EXLCZ)993400000000102778 100 $a20130109d2013 uy 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt 182 $cc 183 $acr 200 00$aStudying stellar rotation and convection $etheoretical background and seismic diagnostics /$fMariejo Goupil ...[et al.], editors 205 $a1st ed. 2013. 210 $aBerlin ;$aNew York $cSpringer$dc2013 215 $a1 online resource (XI, 261 p. 85 illus., 46 illus. in color.) 225 1 $aLecture notes in physics,$x0075-8450 ;$vv.865 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-642-33379-6 320 $aIncludes bibliographical references and index. 327 $aRotation and Associated Seismology -- Modeling and Rotating Stars -- 2D Oscillation of Rotating Stars -- Seismology of Rotating Stars -- Convection and Associated Seismology -- Turbulent Convection in Stellar Surface Layers -- Dynamical Instabilities. 330 $aThis volume synthesizes the results of work carried out by several international teams of the SIROCO (Seismology for Rotation and Convection) collaboration. It provides the theoretical background required to interpret the huge quantity of high-quality observational data recently provided by space experiments such as CoRoT and Kepler. Asteroseismology allows astrophysicists to test, to model and to understand stellar structure and evolution as never before. The chapters in this book address the two groups of topics summarized as "Stellar Rotation and Associated Seismology" as well as "Stellar Convection and Associated Seismology". The book offers the reader solid theoretical background knowledge and adapted seismic diagnostic techniques. 410 0$aLecture notes in physics ;$v865. 606 $aStars$xRotation 606 $aStellar oscillations 615 0$aStars$xRotation. 615 0$aStellar oscillations. 676 $a523.83 701 $aGoupil$b M.-J$g(Marie-Jo),$f1957-$01762318 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910130580903321 996 $aStudying stellar rotation and convection$94202178 997 $aUNINA